<sup>18</sup>F-FDG PET for Neurodegenerative Diseases: Principles and Progress
Issued Date
2025-01-01
Resource Type
ISSN
08932336
eISSN
19406045
Scopus ID
2-s2.0-105004241491
Journal Title
Neuromethods
Volume
222
Start Page
85
End Page
105
Rights Holder(s)
SCOPUS
Bibliographic Citation
Neuromethods Vol.222 (2025) , 85-105
Suggested Citation
Thientunyakit T., Wannasoupol N., Sethanandha C., Piyapittayanan S., Siriprapa T., Thongpraparn T., Muangpaisan W., Gelovani J. <sup>18</sup>F-FDG PET for Neurodegenerative Diseases: Principles and Progress. Neuromethods Vol.222 (2025) , 85-105. 105. doi:10.1007/978-1-0716-4494-2_6 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/110028
Title
<sup>18</sup>F-FDG PET for Neurodegenerative Diseases: Principles and Progress
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
The prevalence of neurodegenerative diseases has been increasing in aging society. Recent developments in several biomarkers help understand the underlying principles of neurodegenerative diseases and accelerate remarkable progress in clinical practice and research. Here, we describe a prospective study on the use of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) of the brain as a predictive marker for response to treatment in patients with Alzheimer’s disease and compare results with other imaging markers, including amyloid PET, MRI, and the integrated imaging marker using amyloid PET, FDG PET, and MRI. We aim to provide the readers with guidelines on applying both qualitative and semiquantitative and integrating FDG PET data with other imaging markers. The research challenges and possible measures to overcome those challenges are also discussed.